According to the Bank of China Securities Research Report, Hengrui Pharmaceutical's net profit attributable to shareholders of listed companies in 24 was 6.337 billion yuan, an increase of 47.28% over the previous year. The company maintained steady growth, was optimistic about the company's leading position and pipeline value of innovative platforms, and maintained a “buy” rating. The company's annual performance grew rapidly. On the one hand, the impact of collection on the company's generic drugs has gradually been eliminated, and the company's innovative drugs have begun to be rapidly released; on the other hand, the company's overseas BD has also gradually entered the harvest period. In 2024, the company received licensing cooperation consideration such as Merck Healthcare's 160 million euro down payment for external licensing and 100 million US dollars for external licensing, further bringing performance flexibility to the company. On a quarterly basis, Q4 achieved revenue of 7.795 billion yuan in a single quarter, up 34.26% year on year, net profit to mother was 1,717 billion yuan, up 107.20% year on year; net profit after deducting non-return to mother was 1,562 billion yuan, up 99.94% year on year, and maintained rapid growth in the fourth quarter.

According to the Bank of China Securities Research Report, Hengrui Pharmaceutical's net profit attributable to shareholders of listed companies in 24 was 6.337 billion yuan, an increase of 47.28% over the previous year. The company maintained steady growth, was optimistic about the company's leading position and pipeline value of innovative platforms, and maintained a “buy” rating. The company's annual performance grew rapidly. On the one hand, the impact of collection on the company's generic drugs has gradually been eliminated, and the company's innovative drugs have begun to be rapidly released; on the other hand, the company's overseas BD has also gradually entered the harvest period. In 2024, the company received licensing cooperation consideration such as Merck Healthcare's 160 million euro down payment for external licensing and 100 million US dollars for external licensing, further bringing performance flexibility to the company. On a quarterly basis, Q4 achieved revenue of 7.795 billion yuan in a single quarter, up 34.26% year on year, net profit to mother was 1,717 billion yuan, up 107.20% year on year; net profit after deducting non-return to mother was 1,562 billion yuan, up 99.94% year on year, and maintained rapid growth in the fourth quarter.